[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 28, 2010

Evidence Strength in FDA Premarket Approval of Cardiovascular Devices—Reply

JAMA. 2010;303(16):1599-1601. doi:10.1001/jama.2010.512

In Reply: We agree with Dr Kong and colleagues that the evidence used by regulators should represent best available science. In our view, however, researchers are not presenting the best available science. For the highest-risk medical devices, only 14% of studies were blinded, 27% randomized, and only half used controls (31% of which were retrospectively selected). In addition, 88% of primary end points in the studies were surrogate outcomes, and large numbers of enrolled patients were frequently excluded from safety and efficacy analyses.

First Page Preview View Large
First page PDF preview
First page PDF preview
×